On Monday, Seres Therapeutics Inc (NASDAQ: MCRB) was -1.76% drop from the session before settling in for the closing price of $0.82. A 52-week range for MCRB has been $0.54 – $2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 386.36%. When this article was written, the company’s average yearly earnings per share was at 11.81%. With a float of $118.92 million, this company’s outstanding shares have now reached $135.04 million.
The extent of productivity of a business whose workforce counts for 233 workers is very important to gauge. In terms of profitability, gross margin is -1918.98%, operating margin of -43457.49%, and the pretax margin is -43343.58%.
Seres Therapeutics Inc (MCRB) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Seres Therapeutics Inc stocks. The insider ownership of Seres Therapeutics Inc is 30.13%, while institutional ownership is 27.23%. The most recent insider transaction that took place on Oct 28 ’24, was worth 2,991. In this transaction an insider of this company sold 4,334 shares at a rate of $0.69, taking the stock ownership to the 30,423 shares. Before that another transaction happened on Oct 28 ’24, when Company’s See Remarks sold 3,984 for $0.69, making the entire transaction worth $2,749. This insider now owns 75,885 shares in total.
Seres Therapeutics Inc (MCRB) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 11.81% per share during the next fiscal year.
Seres Therapeutics Inc (NASDAQ: MCRB) Trading Performance Indicators
You can see what Seres Therapeutics Inc (MCRB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.89. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 372.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of Seres Therapeutics Inc (MCRB)
The latest stats from [Seres Therapeutics Inc, MCRB] show that its last 5-days average volume of 2.53 million was inferior to 4.4 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 84.19%. Additionally, its Average True Range was 0.07.
During the past 100 days, Seres Therapeutics Inc’s (MCRB) raw stochastic average was set at 17.89%, which indicates a significant decrease from 67.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.39% in the past 14 days, which was lower than the 108.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8797, while its 200-day Moving Average is $0.9313. Now, the first resistance to watch is $0.8397. This is followed by the second major resistance level at $0.8721. The third major resistance level sits at $0.8959. If the price goes on to break the first support level at $0.7835, it is likely to go to the next support level at $0.7597. The third support level lies at $0.7273 if the price breaches the second support level.
Seres Therapeutics Inc (NASDAQ: MCRB) Key Stats
There are 170,200K outstanding shares of the company, which has a market capitalization of 137.77 million. As of now, sales total 126,330 K while income totals -113,720 K. Its latest quarter income was 0 K while its last quarter net income were -40,130 K.
